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Background: Preeclampsia, a pregnancy complication of placental origin is associated with altered expression of
angiogenic factors and their receptors. Recently, there is considerable interest in understanding the role of adverse
intrauterine conditions in placental dysfunction and adverse pregnancy outcomes. Since we have observed
changes in placental global DNA methylation levels in preeclampsia, this study was undertaken to examine gene
promoter CpG methylation and expression of several angiogenic genes.
We recruited 139 women comprising, 46 normotensive women with term delivery (≥37 weeks), 45 women with
preeclampsia delivering preterm (<37 weeks) and 48 women with preeclampsia delivering at term. Expression levels
and promoter CpG methylation of VEGF, FLT-1 and KDR genes in placentae from respective groups were
determined by Taqman-based quantitative real time PCR and by the Sequenom® EpiTYPER™ technology
respectively.
Results: We observed several differentially methylated CpG sites in the promoter regions of VEGF, FLT-1 and KDR
between the normotensive and preeclampsia groups. We specifically observed hypomethylated CpGs in the
promoter region and an increased expression of VEGF gene between term and preterm preeclampsia. However,
mean promoter CpG methylation could not account for the higher expression of FLT-1 and KDR in preterm
preeclampsia as compared to normotensive group.
Conclusions: Our data indicates altered DNA methylation patterns in the VEGF, FLT-1 and KDR genes in
preeclampsia as compared to the normotensive group, which could be involved in the pathophysiology of
preeclampsia. Hypomethylation of VEGF promoter and consequent upregulation of VEGF mRNA levels could be a
compensatory mechanism to restore normal angiogenesis and blood flow in preterm preeclampsia. This study
suggests a role of altered DNA methylation in placental angiogenesis and in determining adverse pregnancy
outcomes.Background
Preeclampsia (PE) originates in the placenta and involves
inadequate cytotrophoblast invasion, maternal endothelial
dysfunction and altered expression of angiogenic and anti-
angiogenic factors, which ultimately leads to various clin-
ical manifestations [1]. Vasculogenesis and angiogenesis
are considered to be central processes in the development* Correspondence: srjoshi62@gmail.com
†Equal contributors
1Department of Nutritional Medicine, Interactive Research School for Health
Affairs, Bharati Vidyapeeth University, Pune 411043, India
Full list of author information is available at the end of the article
© 2013 Sundrani et al.; licensee BioMed Centr
Commons Attribution License (http://creativec
reproduction in any medium, provided the orof the placenta and are mainly controlled by vascular
endothelial growth factor (VEGF). Altered levels of
VEGF and its receptors can disrupt angiogenesis, lead-
ing to placental insufficiency and endothelial dysfunc-
tion seen in PE [2]. VEGF exerts its biological effects
through two high-affinity tyrosine kinase receptors
namely, vascular endothelial growth factor receptor-1
(VEGFR-1)/fms-like tyrosine kinase-1 (FLT-1), and vascular
endothelial growth factor receptor-2/kinase insert domain
containing receptor (KDR). FLT-1 interactions with VEGF
are critical for invasion and pseudo-vasculogenesis while
KDR is a major mediator of mitogenic and angiogenical Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Maternal and neonatal characteristics
Normotensive Term PE Preterm PE
(n = 46) (n = 48) (n = 45)
Maternal characteristics
Age, yrs 22.9 ± 3.2 23.1 ± 2.9 23.9 ± 4.2
Weight, kg 52.1 ± 8.2 52.0 ± 11.2 47.7 ± 6.6*1
Height, cm 152.7 ± 4.9 152.3 ± 7.2 150.7 ± 5.4
Body mass index, kg/m2 22.3 ± 3.4 22.4 ± 4.8 20.9 ± 2.7
Gestation, wks 39.0 ± 1.2 38.6 ± 1.1 34.2 ± 1.9**1
Education, grade 9.2 ± 4.0 9.8 ± 3.5 9.4 ± 3.9



















Nulliparous 42.6 68.9 58.5
Multiparous 57.4 31.1 41.5
Mode of delivery, %
Normal delivery 70.2 78.3 45.2
Caesarean section 29.8 21.7 54.8
Neonatal characteristics
Gender of fetus, %
Male 54.3 51.1 42.9
Female 45.7 48.9 57.1
APGAR score (1 minute) 7.7 ± 1.2 7.6 ± 1.2 6.6 ± 1.8**1
APGAR score (5 minute) 8.6 ± 0.7 8.8 ± 0.7 8.1 ± 1.0**1
Weight, kg 2.9 ± 0.3 2.7 ± 0.5** 1.9 ± 0.5**1
Length, cm 48.1 ± 2.6 48.1 ± 2.4 43.8 ± 4.4**1
Head circumference, cm 33.9 ± 1.3 33.3 ± 1.7 30.3 ± 3.0**1
Chest circumference, cm 32.3 ± 1.4 31.7 ± 2.1 27.1 ± 2.9**
Values given are mean ± SD, unless stated otherwise. PE, preeclampsia.
*P <0.05; **P <0.01 when compared to term; 1P <0.01 when compared to
term PE.
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survival [3].
A number of studies have examined the mRNA levels
of different angiogenesis regulating factors in placentae
from PE patients although results are inconsistent. Some
studies report increased VEGF expression [4-7], while
others report reduced expression [8-10] in preeclamptic
women. Other studies found no difference in VEGF expres-
sion [11-13]. Similarly expression of FLT-1 [14-16] and
KDR [11,16,17] have also been examined. Very few studies
have simultaneously examined the expression of VEGF and
both its receptors in the human placenta in PE [18,19].
Further, most of the reported studies have been carried
out on small sample sizes and are limited by the broad
range of gestational ages.
Healthy placental development involves spatio-temporally
programmed gene expression patterns and any alteration in
this process may compromise placental function [20-22].
Under suboptimal uterine conditions, normal methylation
of DNA is disrupted, thereby altering gene expression and
preventing normal growth [23]. The placenta serves as the
interface between the mother and fetus. A number of en-
vironmental factors such as diet, smoking, stress, behavior
and assisted reproductive techniques have been reported
to influence the methylation and expression of various
genes in the human placenta as well as from other animals
[24,25]. We have earlier observed increased homocysteine
and oxidative stress levels in PE [26] and shown associ-
ation of alterations in placental global DNA methylation
levels with homocysteine levels and blood pressure [27].
The objective of this study was to examine the methyla-
tion of the promoters of the VEGF, FLT-1 and KDR genes
and their mRNA levels in placentae from women diag-
nosed with PE as compared to normal pregnancies. We
further investigated whether the gene expression levels
were related to promoter CpG methylation levels. To the
best of our knowledge, no study to date has investigated
the methylation patterns of the angiogenic gene VEGF
and its receptors in the human placentae in PE.
Results
Maternal and neonatal characteristics
The maternal and neonatal characteristics are given in
Table 1. All the women recruited in the study had similar
age, income and education. The frequency of consumption
of foods rich in folic acid, vitamin B12 and omega-3 fatty
acids was similar in normotensive and both the PE groups
as reported by us earlier [26,28]. The body weight and ges-
tational age at delivery were significantly lower (P <0.05)
in women with PE who delivered preterm. The maternal
systolic and diastolic blood pressures were significantly
higher in the term and preterm PE groups compared to the
normotensive group. Newborn weight was significantly
reduced (P <0.01) in the term PE group as compared to thenormotensive group. The newborn weight, height, head cir-
cumference, chest circumference and APGAR score at 1
minute and 5 minutes were significantly lower (P <0.01)
in the preterm preeclampsia group compared to the
normotensive and term PE groups.Promoter CpG methylation of VEGF, FLT-1 and KDR genes
We analyzed cytosine methylation at 23 CpG sites in the
VEGF promoter region, 30 CpG sites in the FLT-1 pro-
moter region and 37 CpG sites in the KDR promoter. The
mean percent methylation at all CpG sites in the promoter
regions of the three genes are given in Additional file 1.
The mean percent methylation at the differentially methyl-
ated CpG sites in the promoter regions of the three genes
are given in Table 2. The mean methylation level of the
VEGF promoter was significantly lower (P <0.05) in the
Table 2 Mean percent methylation levels at the
differentially methylated CpG sites in the promoter
region of the VEGF, FLT-1 and KDR genes
Percent methylation (%)
CpG site Mean ± standard error
Normotensive Term PE Preterm PE
VEGF
Mean promoter 5.1 ± 0.1 4.9 ± 0.1 4.7 ± 0.2*
CpG - 6.7 4.2 ± 0.2 3.7 ± 0.2 3.5 ± 0.4*
CpG – 8 7.1 ± 0.1 6.8 ± 0.1 6.4 ± 0.2**
CpG – 14 4.2 ± 0.3 4.9 ± 0.3 5.2 ± 0.4*
FLT-1
CpG – 16 1.6 ± 0.2 0.8 ± 0.2** 1.2 ± 0.2
CpG – 17 3.2 ± 0.1 3.2 ± 0.1 2.7 ± 0.1*1
CpG – 24 1.1 ± 0.1 0.7 ± 0.1* 0.6 ± 0.1*
KDR
CpG – 12.13 4.9 ± 0.7 7.6 ± 1.1* 8.2 ± 1.1*
Values given are mean ± SE. PE, preeclampsia. *P <0.05; **P <0.01 compared
to term; 1P <0.05 compared to term PE.
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The mean methylation at the CpG site 6.7 (P <0.05) and
CpG site 8 (P <0.01) was significantly reduced, whereas
that at CpG site 14 was significantly higher (P < 0.05) in
the preterm PE group compared to the normotensive
group (Figure 1). The mean methylation level of theFigure 1 Mean promoter methylation levels and differentially methyl
VEGF CpG site 6.7; (C) VEGF CpG site 8; (D) VEGF CpG site 14. *P <0.05FLT-1 gene promoter was similar between the groups.
The mean methylation at CpG site 16 in the FLT-1 pro-
moter region was significantly reduced (P <0.01) in the
term PE group as compared to the normotensive group,
while mean methylation at CpG site 17 was significantly
reduced (P <0.05) in the preterm PE group compared to
the normotensive group. Further mean methylation at
the CpG site 24 was significantly reduced (P <0.05) in
both the term and the preterm PE group compared to the
normotensive group (Figure 2). There was no significant
difference in mean methylation level of the KDR gene
promoter between the three groups. We observed signifi-
cantly higher mean methylation at CpG site 12.13 in the
KDR gene promoter region in term PE (P <0.05) and pre-
term PE (P <0.01) group compared to the normotensive
group (Figure 3). Further, several transcription factor bind-
ing sites were predicted in the promoter region of VEGF,
FLT-1 and KDR genes (Additional file 2).VEGF, FLT-1, and KDR gene expression levels in placenta
The placental gene expression levels of VEGF were signifi-
cantly lower in the term PE group than in the normoten-
sive group (P <0.05), while the levels were significantly
higher (1.6-fold) in the preterm PE group compared to the
normotensive group. The gene expression levels of FLT-1
and KDR were comparable in the normotensive and term
PE groups but were higher (1.9-fold for FLT-1 and 3.0-foldated sites in the VEGF promoter: (A) VEGF Mean Promoter; (B)
compared to normotensive group. PE, preeclampsia.
Figure 2 Mean promoter methylation levels and differentially methylated sites in the FLT-1 promoter: (A) FLT-1 Mean Promoter; (B)
FLT-1 CpG site 16; (C) FLT-1 CpG site 17; (D) FLT-1 CpG site 24. *P <0.05 and **P <0.01 compared to normotensive group; @P <0.05
compared to the term PE group. PE, preeclampsia.
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PE (P <0.05 for FLT-1 and P <0.01 for KDR) and the
normotensive group (P <0.01) (Figure 4).
Association between CpG methylation and gestation
Mean promoter methylation of the VEGF gene was
negatively (n = 24, r = −0.461, P = 0.018) associated with
gestation in the term PE group but not in the normoten-
sive and preterm PE groups. Further CpG site 6.7 in the
VEGF promoter region was negatively associated with
both the term PE (n = 24, r = −0.399, P = 0.044) and
preterm PE gestations (n = 19, r = −0.463, P = 0.034).
Mean promoter methylation in the FLT-1 gene was notFigure 3 Mean promoter methylation levels and differentially methyl
Mean Promoter. *P <0.05 and **P <0.01 as compared to normotensive grassociated with gestation in any of the groups. However,
CpG site 16 showed a positive association with preterm
PE gestation (n = 30, r = 0.420, P = 0.020). There were
no associations between methylation and gestation in
the KDR gene promoter region.
Associations between CpG methylation and gene
expression
The mean methylation at CpG site 6.7 in the VEGF pro-
moter region was positively associated with VEGF gene
expression levels in the term PE group (n = 36, r = 0.331,
P = 0.049). The mean methylation at CpG site 16 in the
FLT-1 promoter region was negatively associated withated sites in the KDR promoter: (A) KDR CpG site 12.13; (B) KDR
oup. PE, preeclampsia.
Figure 4 Gene expression levels in normotensive and preeclamptic groups: (A) VEGF Gene Expression; (B) FLT-1 Gene Expression; (C)
KDR Gene Expression. *P <0.05 and **P <0.01 when compared to normotensive group; @P <0.05 and @@ P <0.01 when compared to the Term
PE group. PE, preeclampsia.
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(n = 32, r = −0.392, P = 0.026). In contrast mean methyla-
tion at CpG site 24 in the FLT-1 promoter region was posi-
tively associated with FLT-1 gene expression in the preterm
PE group (n = 30, r = 0.434, P = 0.017). Further the mean
methylation at CpG site 12.13 in the KDR promoter region
was negatively associated with KDR gene expression in the
term PE group (n = 30, r = −0.369, P = 0.045).
Discussion
In this study, we examined the CpG methylation of
VEGF, FLT-1 and KDR gene promoters and their expres-
sion in human placentae. These genes encode important
proteins that determine placental angiogenesis. This
study shows several interesting findings: 1) some CpG
sites in the promoter regions of these genes showed dif-
ferential methylation between the normotensive, term
and preterm PE groups; 2) mean promoter methylation
in the VEGF gene was significantly lower in the preterm
PE group compared to normotensive, while it was compar-
able between normotensive and term PE group; 3) VEGF
expression was significantly higher in the preterm PE com-
pared to the normotensive group, while it was lower in the
term PE group; 4) although mean methylation in the FLT-
1 and KDR promoters was similar between the three
groups, FLT-1 and KDR gene expression was significantly
higher in the preterm PE group compared to the term PE
and the normotensive group; 5) mean methylation at the
VEGF promoter and methylation at some differentiallymethylated CpG sites in the VEGF and FLT-1 promoters
was associated with term and preterm gestations, and
6) mean methylation at some differentially methylated
CpG sites in the VEGF, FLT-1 and KDR promoters was
associated with their gene expression levels.
DNA methylation is an important epigenetic mechanism
of gene regulation. In the VEGF, FLT-1 and KDR promoter
regions, some CpG sites were differentially methylated be-
tween the normotensive and PE groups. These results indi-
cate possible involvement of altered DNA methylation
patterns in these genes, which could be involved in the
pathophysiology of PE. In humans, DNA methylation is
mediated by DNA methyltransferases that are responsible
for de novo methylation and maintenance of methylation
patterns during replication. There is abundant evidence
that suggests that DNA methylation patterns can be altered
as a component of disease pathogenesis [29,30]. However,
further studies are needed to determine the functional
relevance of these findings in the pathophysiology of PE.
Alterations in methylation status within promoter re-
gions can affect gene expression and hence the phenotype
[31]. Our results show an increase in VEGF mRNA in pre-
term PE compared to term PE and normotensive pla-
centas. It has been suggested that in severe PE, higher
levels of placental hypoxia inducible transcription factors
upregulate VEGF expression [32]. Upregulation of VEGF
in preterm the PE placenta is suggestive of a compensa-
tory mechanism attempting to normalize angiogenesis
and blood flow. Furthermore, the VEGF promoter (mean
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in the preterm PE group and this may be responsible for
the increased expression of VEGF observed in this group.
These results are consistent with other reports that sug-
gest an inverse relationship between promoter CpG
methylation and gene expression and indicate epigenetic
control of VEGF expression in preterm PE [33,34]. It is
also possible that the CpG sites 6.7, 8 and 14, which are
differentially methylated in the preterm PE group com-
pared to the normotensive group, may be involved in the
upregulation of VEGF mRNA levels.
Although the mean methylation of the VEGF promoter
was comparable between the normotensive and term PE
group, the gene expression levels were significantly lower
in the term PE group compared to the normotensive
group. Generally, the pathology of preterm PE is regarded
as more severe compared to term PE. Previous studies
have suggested the existence of different subsets of PE and
that pathophysiologic mechanisms may contribute differ-
ently to the development of preterm versus term PE
[35,36]. It is likely that since term PE is less severe com-
pared to preterm PE, the compensatory increase in VEGF
mRNA levels is not observed, neither is there a difference
in the promoter methylation levels. The observed decrease
in VEGF expression in the term PE may be due to alterna-
tive pathways of gene expression regulation such as alter-
ations in transcription factor expression or histone
modifications as a consequence of the pathology. Some
previous studies have also shown reduced placental VEGF
mRNA levels at term in the PE compared to the normo-
tensive group [9,19].
Mean methylation of the FLT-1 and KDR promoters
was comparable between groups, yet the mRNA levels of
FLT-1 and KDR were significantly higher in the preterm
PE group compared to the other two groups. Although
there was no difference in the mean promoter methyla-
tion in the FLT-1 gene promoter, CpG site 17 was sig-
nificantly hypomethylated in the preterm PE group
compared to the normotensive and term PE group.
This site may be important in influencing the FLT-1
expression in preterm PE, however further studies are
needed to determine the exact role of this site in the
regulation of FLT-1 expression. Further KDR expres-
sion in preterm PE may not be mediated through
DNA methylation changes but through other factors
affecting gene expression such as transcription fac-
tors, mRNA stability and histone modifications.
Modulation of factors affecting gene expression by
intracellular signals in different physiological states is
well established. The opposite trends in VEGF, FLT-1
and KDR mRNA levels and the difference in epigen-
etic patterns between these two groups provide further
support for the existence of differences in pathology
between term and preterm PE.Our previous studies have established that omega 3 fatty
acids and micronutrients (folic acid and vitamin B12) are
interlinked in the one carbon cycle [37,38]. Further, we have
also reported decreased omega 3 fatty acids and increased
plasma homocysteine levels in preeclamptic mothers [26].
Since these pathways are major determinants of the methy-
lation potential of the cell, our results could affect DNA
methylation patterns, thereby influencing regulation of vital
genes [39].
Further we attempted to understand the functional rele-
vance of methylation changes by investigating whether the
differentially methylated CpG sites in VEGF, FLT-1 and
KDR gene promoters were located within transcription
factor binding sites. Although, few transcription factor
binding sites were predicted in close proximity of the dif-
ferentially methylated CpG sites in promoter regions of all
three genes, it is difficult to assign importance to these
changes. Further studies are needed to understand the role
of methylation at these CpG sites in regulating the gene
expression through transcription factor binding.
We observed that mean methylation of the VEGF pro-
moter and some differentially methylated sites in the
VEGF and FLT-1 promoters were associated with term
and preterm gestations. CpG 6.7 methylation in the VEGF
promoter was negatively associated with term and preterm
PE gestations. Methylation of CpG 16 in the FLT-1 pro-
moter was positively associated with preterm PE gestation.
Human pregnancy comprises a complex series of differen-
tiation and growth processes that are spatio-temporally
regulated [23]. We have previously reported gestation-
dependent changes in placental global DNA methylation
[20]. Novakovic et al. (2009) have reported changes in
promoter CpG methylation (both increase and decrease
in methylation) with gestation in the placenta [40]. In
addition to CpG sites that consistently change over ges-
tation, they also report the existence of CpG sites that
show inter-individual variability within each gestational
age and suggest that such variability could be attributed
to cumulative differences in environmental exposure.
Our results show that mean methylation of some of the
differentially methylated sites in the VEGF, FLT-1 and KDR
promoters were positively or negatively associated with
their gene expression levels. Although hypermethylation is
generally associated with suppression of gene expression,
recent studies have also reported a positive association
between methylation and gene expression [41-43].
Conclusions
To summarize, the CpG methylation patterns and expres-
sion of VEGF differs between the preterm PE and term PE
group and could be causally related to the differences in
pathology of term and preterm PE. We have previously
reported altered one-carbon metabolism, hyperhomo-
cysteinemia and increased oxidative stress in PE, which
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our results could be attributed to these changes in the
intrauterine environment. However, it is unclear whether
the observed differences are a cause or effect of the under-
lying pathophysiology. Nevertheless, this study reiterates
that CpG methylation is dynamic and influenced by the
intrauterine environment. Further, as seen in the case of
the VEGF gene, DNA methylation changes could account
for the alterations in gene expression, and the ability to in-
duce compensatory mechanisms to circumvent adverse
pregnancy outcome. This study also highlights that DNA
methylation may not explain all gene expression changes,
and other mechanisms of gene expression regulation also
come into play. The role of CpG methylation, in other re-
gions in the gene also cannot be ruled out, since it has also
been suggested that methylation changes in the gene body
could also affect expression [44]. This study is the first ac-
count of CpG methylation changes in the VEGF, FLT-1 and
KDR gene promoters in pregnancies complicated by PE.
Methods
Subjects
This study was conducted at the Department of Obstet-
rics and Gynecology, Bharati Hospital, Pune with the
understanding and consent of each subject and was ap-
proved by the Bharati Vidyapeeth Medical College Institu-
tional Ethical Committee. A total number of 139 pregnant
women with singleton pregnancy were recruited for this
study. Of these, 46 women had normotensive pregnancies
and delivered at term, 93 women had PE during preg-
nancy, of which 45 delivered preterm (<37 weeks), while
48 delivered at term (≥37 weeks). Women were excluded
from the study if there was evidence of other pregnancy
complications, such as chronic hypertension, type 1 or
type 2 diabetes mellitus, seizure disorder and renal or liver
disease. All study participants neither consumed alcohol
nor smoked and were from a low socioeconomic group.
The normotensive group consisted of pregnant women
with no medical or obstetric complications. Pregnant
women with eclampsia were excluded from the study.
PE was diagnosed by an obstetrician who is also one of
the investigators in this study (SSM) and PE has been
discussed by us in a number of our earlier studies
[45-47]. PE was defined by systolic and diastolic blood
pressures greater than 140 and 90 mm Hg, respectively,
with presence of proteinuria (>1+ or 300 mg/24 hrs) on
a dipstick test and was confirmed by repeated recording
of the blood pressure with an interval of 6 hrs. Blood pres-
sure was recorded frequently, starting at enrollment and
at every follow up visit, which occurred approximately
once a month until delivery. Response: Yes the preceding
statement may be deleted. The data provided are the
blood pressure values at the time of delivery, that is, just
before going to the labor room, to ensure that a similartime point was used for both groups to rule out the effect
on blood pressure of stress due to labor. Treatment of pre-
eclamptic women included antihypertensive drugs and ar-
ginine supplementation. In severe PE cases, magnesium
sulphate was given intravenously. Gestational age was
based on the day of last menstrual period and was con-
firmed by ultrasound. All women were routinely given
iron and folic acid supplements as per the National
Anemia Prophylaxis Program.
Tissue collection and processing
Fresh placental tissues were obtained from normal and
preeclamptic pregnancies immediately after delivery. Fetal
membranes were trimmed off and small pieces were ran-
domly cut out from the placental cotyledons. Tissue were
rinsed in phosphate-buffered saline to wash off maternal
and fetal blood, snap frozen in liquid nitrogen and stored
at −80°C until assayed.
Gene promoter methylation assay
Genomic DNA was isolated from placental samples using
the DNeasy Blood and Tissue kit (Cat No. 69504, Qiagen,
Hilden, Germany) using the protocol supplied by the
manufacturer. One microgram of purified genomic DNA
was bisulfite-treated using the EZ DNA Methylation™ Kit
(Cat No. D5006, Zymo Research, California, USA) as per
the manufacturer’s instructions. The bisulfite-modified
DNA was used for Sequenom MassARRAY EpiTYPING
for gene-specific methylation analysis of VEGF, FLT-1, and
KDR. In this technique, base-specific cleavage followed by
MALDI-TOF mass spectrometry is used. The size ratio of
the cleaved products provides quantitative methylation
estimates for CpG sites within a target region. Genomic
sequences for assay design were extracted from the
UCSC genome browser (http://www.genome.ucsc.edu/).
Primer pairs for amplification were designed using
EpiDesigner web tool (http://www.epidesigner.com/).
The promoter CpG island sequences used in this study
for CpG methylation analysis of VEGF (Chromosome 6,
43737274 to 43737739), FLT-1 (Chromosome 13, 29067752
to 29068196) and KDR (Chromosome 4, 55991374 to
55991777) were selected using the UCSC genome browser
and are given in Figure 5. For PCR amplification, a T7-
promoter tag was added to the reverse primer for
performing the in vitro transcription, and a 10-mer tag
sequence was added to the forward primer to balance the
PCR primer length. The primers are listed in Table 3.
Bisulfite-treated genomic DNA was amplified using the
designed primers. The thermal cycling conditions were as
follows. For the VEGF- 1 cycle: 95°C for 15 minutes; 5
cycles: 95°C for 1 minutes, 62°C for 2 minutes, 72°C for 2
minutes; 32 cycles: 95°C for 1 minute, 62°C for 1 minute,
72°C for 1 minute then 72°C for 7 minutes. For the FLT-1
and KDR-1 cycle: 95°C for 15 minutes; 5 cycles: 95°C for 1
Figure 5 Promoter sequences selected for analysis of CpG methylation of (A) VEGF (B) FLT-1 and (C) KDR genes. Sequences highlighted
in dark gray indicate primers. Sequences highlighted in light gray indicate CpG sites analyzed.
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95°C for 1 minutes, 60°C for 1 minute, 72°C for 1 minute
then 72°C for 7 minute.
Following PCR amplification, in vitro transcription and
T-cleavage assay was performed using MassCLEAVE™
Reagent Kit (Cat No. 10129, Sequenom). Unincorporated
dinucleotide triphosphates were removed by shrimp alka-
line phosphatase treatment. Typically, 2 μl of the PCR
product was directly used as template for the in vitro tran-
scription reaction. T7 RNA and DNA polymerase was
used to incorporate thymidine triphosphate in the tran-
scripts. In the same step, RNase-A was added to cleave the
in vitro transcripts (T-cleavage assay). Samples were di-
luted with 20 μl of water. Conditioning of the phosphate
backbone was done by adding 6 mg of Clean Resin before
performing MALDI-TOF mass spectrometry (MS)Table 3 Primers used for promoter CpG analysis







* T7-promoter sequence tag -cagtaatacgactcactatagggagaaggct added to reverse p
10-mer sequence tag- aggaagagag added to the forward primer.analysis. For MS analysis RNase-A-treated product was
robotically dispensed onto silicon matrix preloaded chips
(SpectroCHIP Cat No. 10117, Sequenom), and the mass
spectra were collected using a MassARRAY Compact
MALDI-TOF (Sequenom). Methylation data were gener-
ated as β values between 0 and 1, indicating percentage
methylation of the original template. The methylation ra-
tios were generated from the spectra by the EpiTYPER
software v1.0 (Sequenom, California, USA).
Samples that yielded data in greater than 70% for all
CpG units within a promoter were passed for that sample/
promoter pair. For each sample the methylation analysis
was done in duplicates and sites showing more than 10%
difference in methylation were excluded. Sites that were
tagged as low mass or high mass by Epityper software were
also excluded from the analysis. We attempted to predictAmplicon length
(base pairs)
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and KDR promoter regions using the transcription factor
binding site predictor tool, PROMO (version 3.0.2) (http://
alggen.lsi.upc.es/cgi-bin/promo_v3/promo/promoinit.
cgi?dirDB=TF_8.3) [48,49].
Extraction of total RNA, cDNA synthesis and quantitative
real-time (RT)-PCR assays
Total RNA from placenta samples was isolated using the
Trizol method and quantified by the Nanodrop (ND1000
v3.5.2) spectrophotometer. One microgram of total RNA
was transcribed to cDNA using the High-Capacity cDNA
reverse transcription Kit (Cat No. 4368814, Applied
Biosystems, California, USA). RT-quantitative (q)-PCR for
VEGF, FLT-1, KDR mRNAs, and 18S rRNA were
performed with the TaqMan Universal PCR Master Mix
(Cat No. 4324018, Applied Biosystems, California, USA)
using the Applied Biosystems 7500 FAST system. The
relative expression level of the gene of interest was exam-
ined with respect to 18S rRNA to normalize for variation
in the quality of RNA and the amount of input cDNA.
The RT-PCR reactions for each gene were performed in
duplicate. To analyze the RT-PCR results, the average
cycle number (Ct) of the reaction when it crossed a
threshold valued was determined for each reaction.
Differences in Ct (ΔCt) between 18S and the targeted
gene were calculated by subtracting the Ct of the
targeted gene from Ct of 18S. Relative expression levels
of genes were calculated and expressed as 2ΔCt. The
following TaqMan® Gene Expression Assays (Applied
Biosystems, California, USA) were used in this study:
18S RNA (Hs99999901_s1); VEGF (Hs00900058_m1);
FLT-1 (Hs01052936_m1); KDR (Hs00176676_m1).
Statistical analysis
Data were analyzed using SPSS/PC + package (Version
20.0, Chicago, IL, USA). Values are reported as mean ± SD
(demographic characters) or mean ± standard error (SE)
(gene expression and methylation studies). Mean values
of the estimates were compared using one-way ANOVA
and the post hoc least significant difference (LSD) test
at conventional levels of significance (P <0.05). Skewed
variables were transformed to normality using log to the
base 10. The extent of the linear relationship between
several variables was studied using bivariate correlation
analysis.Additional files
Additional file 1: (A) Mean percent methylation at each CpG site in
the VEGF promoter. *P<0.05, ** P <0.01 as compared to control. PE,
preeclampsia; (B) Mean percent methylation at each CpG site in the FLT-1
promoter. * P <0.05, ** P <0.01 as compared to control; @ P <0.05 as
compared to Term PE. PE, preeclampsia; (C) Mean percent methylation ateach CpG site in the KDR promoter. * P <0.05 as compared to control. PE,
preeclampsia.
Additional file 2: Transcription factor binding sites predicted in the
promoter region of (a) VEGF (b) FLT-1 and (c) KDR genes.
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